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Background: Advanced technological aids are frequently used to improve outcome of transbronchial 
diagnostics for peripheral pulmonary lesions. Even when lesion access has been confirmed by 3D imaging, 
obtaining an accurate tissue sample however remains difficult. In this single institution study, we evaluate the 
comparative accuracy of different sampling methodologies and the accuracy of rapid on-site evaluation of 
cytopathology (ROSE) in navigation bronchoscopy cases where imaging has confirmed the catheter to have 
accurately accessed the lesion.
Methods: All consecutive navigation bronchoscopies in between December 2017– June 2020 performed in a 
room with a cone beam CT (CBCT) system where catheter position was intra-procedurally confirmed to be 
within or adjacent to the lesion by cone beam CT and augmented fluoroscopy were included. Individual tool 
outcomes were compared against one another and follow-up outcome. 
Results: A mean of 11.39 samples using 2.93 tools were obtained in 225 lesions (median diameter 15 mm, 
195 patients). A correct diagnosis was most often obtained by forceps (accuracy 70.6%), followed by 1.1 mm 
cryoprobe (68.4%), needle aspiration (46.7%), 1.9 mm cryoprobe (41.2%), brush (30.3%) and lavage (23.7%). 
Procedural outcome corresponded to follow-up outcome in 75.1% of lesions (80.5% of patients). Accurately 
diagnosed lesions were sampled significantly more often (11.91 vs. 9.72 samples, P=0.014). In cases where 
procedural outcome proved malignant, ROSE had also detected this in 47.5%. 
Conclusions: Of all clinically available biopsy tools, the forceps showed most often accurate. However, 
extensive multi-modal sampling resulted in highest diagnostic accuracy. A hypothetical multi-modal approach 
of only using forceps and needle aspiration provided eventual diagnostic outcome in 91.7% of successfully 
diagnosed lesions. In the circumstances of our study, confirmation of malignancy on ROSE did not reduce 
number of biopsies taken nor biopsy time. Future research on how to improve the accuracy and effectivity of 
tissue sampling is needed. 
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Introduction
Despite the development and introduction of several 
technological platforms to help guide the physician in the 
past two decades, obtaining an accurate endobronchial 
diagnosis of small peripheral pulmonary nodules remain 
a challenge. These technological platforms allow for both 
navigation guidance towards a lesion as well as confirming 
accurate lesion access, which become increasingly important 
as lesions are small sized and located peripherally in the 
lung. Techniques include ultrathin bronchoscopy, virtual 
navigation bronchoscopy, electromagnetic navigation, radial 
endobronchial ultrasound probes (rEBUS), robotic assisted 
bronchoscopy and cone beam CT imaging (CBCT) (1-10).
Unfortunately, a confirmed successful navigation does 
not warrant a representative and accurate diagnosis. 
Several studies report the diagnostic yield and procedural 
sensitivity being lower than that of navigation success 
(2,10-12). Furthermore, a study by Coghlin et al. showed 
that the mean % area of samples obtained from visible 
endobronchial lung cancer on histopathology was only 
33.4% and additionally found that 52% of patients had one 
or multiple fragments collected which contained no tumor 
at all (13). As lesions become smaller and are of early stage, 
the margin of error and the nuance become smaller, and 
likely even less samples will reveal the true nature of the 
lesion.
Obtaining accurate tissue samples for analysis is made 
difficult due to small lesion size, tumor heterogeneity, 
and, the ability of making a clear distinction in (early 
state) disease pathology in samples of limited size. The 
concurrent decision-making process on which tissue 
sampling methodology to use and deciding on when 
sufficient material has been collected add to this complexity. 
Additional general characteristics influencing the likelihood 
of a diagnostic outcome are the positioning relative to 
the bronchus, lobes involved, solidness, malignancy 
presence, pleural distance and patient characteristics 
such as emphysema or other co-morbidity (5,14-22). 
As two editorials recently concluded, there’s however 
insufficient evidence to—in general—prefer one overall 
tissue acquisition method over the other, while several 
studies comparing individual technologies and concurrent 
methodologies have been published to date (2,23). Multiple 
studies suggest trans-bronchial needle aspiration (TBNA) 
has good outcome (15,17,18), while the brush, forceps 
and cryobiopsy probes are other commonly available 
and successfully used means (2,15,18,21,24-26). One 
further promising addition to the routine tissue sampling 
methodology is Rapid On-site Evaluation of cytopathology 
(ROSE), providing on-site information on cytology aspirate 
representativeness and the possibility of malignancy. It may 
enhance diagnostic yield and reduce complication rates in 
transbronchial and endobronchial sampling, although there 
is contradiction in results (27-29).
In this single center university hospital study, we 
comparatively assess the different tissue acquisition 
methodologies and the value of ROSE in a cohort of 
patients whom have been navigated to by CBCT guided 
navigation bronchoscopy for small peripheral pulmonary 
nodules. As the 3D CBCT image verification provides for 
tool analysis of only those lesions which have shown to 
be accurately accessed, it provides for a unique analysis. 
This article prospectively analyzes a cohort of consecutive 
patients in accordance with the STARD reporting checklist 
(available at https://dx.doi.org/10.21037/jtd-21-518). By 
relating biopsy tool outcomes per lesion, a direct paired 
comparison of tools is enabled whilst simultaneously 
incorporating clinical decision making on tool use. 
Combined, we report on overall diagnostic tool accuracy 




This study was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013) and took place 
in an experienced university hospital with a dedicated 
pulmonary pathology and interventional pulmonology 
team where navigation bronchoscopy is the first line 
diagnostic procedure for peripheral pulmonary lesions. 
Navigation bronchoscopy under 3D image guidance is only 
performed in those lesions where advanced navigation and/
or confirmation is deemed necessary. The need of advanced 
3D imaging in addition to r-EBUS imaging or conventional 
C-arm fluoroscopy was based upon physician estimation 
of procedure difficulty taking into account lesion size and 
location (>2nd order branches beyond segmental bronchi 
or no bronchus sign). In this study, only cases subject to 
the CBCT guided navigation bronchoscopy were included 
where 3D confirmation of lesion access was available. All 
patients receiving a CBCT guided navigation bronchoscopy 
for diagnosis of a peripheral pulmonary lesion in the 
period of December 2017 to June 2020 were eligible and 
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prospectively approached for written informed study 
consent. Study approval was obtained by the independent 
local medical ethical committee (Arnhem-Nijmegen) 
and institutional review body (No: 2019-5148), informed 
consent was taken from all the patients. Patients in which a 
CBCT guided navigation setting was deemed unnecessary 
due to intra-procedural findings, or, patients in whom the 
lesion could not be successfully reached as verified by 3D 
CBCT, were excluded for analysis. After exclusion, only 
study subjects and concurrent peripheral lesions for which 
successful lesion access had been verified by means of 
navigation bronchoscopy remained for analysis (Figure 1).
Cone Beam CT guided
Navigation bronchoscopy cases
(Dec 2017-June 2020, n=243)
Sampling technique evaluation (n=195 patients, 225 lesions)
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Figure 1 Flow diagram on study inclusion. Unsuccessful navigations were classified as those where imaging showed that the lesion was 
not successfully reached. A non-routine procedure indicated the primary reason for navigation bronchoscopy was other than diagnostics or 
different than normal procedural work-up due to study or clinical causes. ROSE was available only per analysis of brush and TBNA smears. 
TBNA, trans-bronchial needle aspiration; ROSE, rapid on-site evaluation of cytopathology. 
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Study method
Conventional bronchoscopes with 2.8 mm working channel 
(EB19-J10, Pentax Medical, Japan) and consecutive 2.6 mm 
catheters (Olympus medical guide sheath, Tokyo, Japan & 
Medtronic extended working channels, Minneapolis, USA) 
were used to navigate. Navigation was performed by one 
or a combination of electromagnetic navigation guidance 
(Medtronic SuperDimension), rEBUS (Olympus UM-
S20-17S) and CBCT imaging with augmented fluoroscopy 
(Philips Allura/Azurion, Best, The Netherlands or Siemens 
Zeego, Forcheim, Germany). The procedures took place 
under general anesthesia. After navigation, lesion access was 
verified by at least CBCT and augmented fluoroscopy, but 
rEBUS was also often additionally used. 
After confirming navigation success, the catheter 
remained positioned near or within the lesion throughout 
biopsy specimen acquisition. Biopsy specimen acquisition 
was performed with intermittent augmented fluoroscopy, 
CBCT and/or rEBUS imaging. All tool use and the amount 
of sampling was decided upon by the endoscopy team while 
taking into account factors such as safety, hypothesized 
efficacy, needed diagnostic testing and lesion characteristics. 
The intermittent ROSE outcome of individual samples 
was used to decide upon the need of additional sampling. 
With the tools that were decided upon, biopsy specimen 
acquisition was routinely performed in the following order; 
brushing, TBNA, followed by forceps and/or cryobiopsy 
and lavage. Sampling was routinely started using brush 
or TBNA. Based on the CBCT and/or rEBUS imaging 
outcomes, we estimated which tool had highest chance 
of accurately accessing the target lesion and obtaining a 
sample. Typically, when a bronchus sign was identified and/
or rEBUS showed central access in a solid lesion, a brush 
was first obtained. In other cases, TBNA was the first 
tool of choice. Lavage was performed lastly and included 
injection of 10 to up to 60 mL of 0.9% saline through the 
catheter or endoscope. Subsequent 0.9% saline retrieval 
was attempted by suction until deemed sufficient for 
analysis. Brushing for cytopathology was performed by a 
pushing-pulling technique of the complete 1.8 mm brush 
in and out of the catheter (Olympus BC-202D-2010 brush, 
Medtronic SuperDimension cytology brush or Medi-
globe cytology brush, Achenmühle, Germany). Needle 
aspiration was predominantly performed with 18G needles 
(Broncus FleXNeedle, San Jose, USA) by means of a 
similar motion as to that of the brush, with suction being 
applied by syringe proximally. Twenty-one gauge and 19G 
needles of other manufacturers were less often used, based 
upon commercial primary needle availability (Medtronic 
SuperDimension Aspirating Needle). Typically at least three 
aspirations were obtained with approximately ten strokes 
per aspiration. Serrated or non-serrated oval forceps of 
1.8 mm diameter were used to acquire histology specimens 
(Boston Scientific Pediatric Radial Jaw 4 or Olympus FB-
233D biopsy forceps). After advancement through the 
catheter, the forceps were opened and further pushed into 
the lumen until traction could be felt, after which they were 
closed and retracted for histology specimen collection. 
Cryobiopsy for histopathology was available only through 
a 1.9 mm cryoprobe until September 2019, after which a 
1.1 mm version also became available (Erbe Elektromedizin, 
Tuebingen, Germany). Due to probe and sample size, the 
1.9 mm cryoprobe had to be removed along with catheter 
and endoscope after an initial freeze of 4–7 s. Oppositely, the 
catheter could be left in place for repeated sampling with the 
1.1 mm cryoprobe. Freezing during 5–9 s was followed by 
removal of the 1.1 mm probe for histopathology collection.
Individual brush and TBNA cytology samples were 
divided onto two slides; one Giemsa staining which was also 
used for ROSE and one slide for Papanicolaou smearing 
used only for definitive analysis. Remaining material was 
collected for cell block. Separate collection containers were 
used for every sampling tool. ROSE was available for all 
cases included in this study, which in our center is performed 
by a dedicated team of three experienced and trained 
cytopathology technicians who are routinely involved in 
all navigation bronchoscopy, EBUS, EUS and ultrasound 
guided TTNA procedures performed (totaling >6,000 
procedures in the past decade). The ROSE procedure took 
place at the interventional pulmonology suite, such that two-
way communication was easily maintained.
Statistical analysis
Descriptive parameters are presented as counts and 
percentages, along with medians, means and ranges. All 
individual tool outcomes and concurrent individual nodules 
were correlated to a procedural outcome and a golden 
standard follow-up outcome. Golden standard follow-up was 
either the final pathology diagnosis from surgical resection, 
additional CT guided TTNA and/or clinical follow-up with 
CT for at least 6 months was considered definitive. The 
comparative accuracy of tools was determined by pairing 
tool outcome in cases of individual lesions where two or 
more tools were used. The McNemar chi-squared test was 
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used to test equivalence of tool accuracy. Wilcoxon testing 
was performed for comparison on not-normally distributed 
data. Student’s t-tests were used to test accuracy differences 
between unpaired data. Tests with a P value of <0.05 
were considered significant. For evaluation of ROSE, all 
procedures where ROSE was performed were included for 
analysis. The concordance of procedural malignant ROSE 
outcome by all cytological specimens was compared with 
both final procedural cytology as well as procedural histology 
outcome. R and RStudio were used for statistical analysis (30).
Results
A total of 195 patients received successful navigation 
bronchoscopy as verified by CBCT and augmented 
fluoroscopy imaging, in which a total of 225 lesions 
were shown to be successfully reached (Figure 1, Table 1). 
Malignant disease was found in 76% of patients. Median 
lesion diameter was 15.0 mm (range, 5–65 mm). Lesions 
were pure ground glass or part solid in 7.1% and 15.1% 
of cases, respectively. The procedural outcome (whilst 
navigation had showed successful) corresponded to gold 
standard outcome in 80.5% of cases on a per patient basis, 
and 75.1% of cases on a per lesion basis. 
Comparative tissue sampling method accuracy
Analysis of individual tissue sampling methods revealed 
forceps biopsy was most often found accurate (70.6%), 
followed by 1.1 mm cryoprobe findings (68.4%), TBNA 
(46.7%), 1.9 mm cryoprobe (41.2%) and tiers brush 
(30.3%) and lavage (23.7%). The pair-wise tool comparison 
substantiated these accuracy findings (Figure 2). The 
forceps showed superior accuracy when directly compared 
against all cytology techniques (brush, TBNA, lavage 
P<0.01), but was not significantly better than pooled 1.1 and 
1.9 mm cryobiopsy accuracy (P=0.081). Pooled 1.1 mm and 
1.9 mm cryobiopsy had significantly better accuracy than 
lavage and brush (P<0.05), but not TBNA (P=0.40). The 
1.1 mm cryoprobe was more often accurate than the 1.9 mm 
cryoprobe (68.4% vs. 41.2%, respectively).
Analysis of a multi-modal sampling approach revealed 
sampling using forceps combined with TBNA would 
have provided eventual diagnostic outcome in 155 out of 
169 successfully diagnosed lesions (91.7%). In the cases 
where these were not diagnostic (n=14), sampling by 1.1 mm 
and 1.9 mm cryoprobe correctly diagnosed 2 and 8 lesions 
whilst brushing and lavage were accurate in 4 and 3 lesions, 
respectively.
Cytology versus histology
The cytology findings (brush, TBNA, lavage) corresponded 
to gold standard follow-up outcome in 49.3% of lesions 
(107/217, Table 2). Histology findings (by forceps and 
cryobiopsy) were more often found accurate (72.4%), but 
the combination of both cytology and histology remained 
most accurate (75.1%). Analysis of data wherein both 
cytology and histology were obtained shows histology was 
significantly more often accurate, be it either malignant 
or benign (Table 2, P value <0.01). The histology outcome 
by itself was significantly more often accurate in benign 
lesions than in malignant lesions (P<0.01, 88.6% vs. 66.9%, 
respectively). This finding did not similarly hold for 
cytology outcome (48.5% accuracy in benign lesions and 
51.9% accuracy in malignant lesions, Table 2). 
Extensive multi-modal sampling
Analysis of sampling method accuracy shows lesions whom 
were accurately diagnosed were subjected to a significantly 
higher amount of sampling (Table 3, P=0.014). An average of 
3.83 separate cytology samples (range, 0–15) and 7.56 separate 
Table 1 Patient, lesion and procedural characteristics 
Variables Number
Patients/lesions (successfully accessed) 195/225
Age, mean [range] (years) 65.2 [36–85]
Gender (M/F) 103/92
Malignancy prevalence (pt./lesion) 76%/75%
Benign disease follow-up, median [range] 
(days)
491 [215–1,224]
Nodule size, median [range] (mm) 15 [5–65]
Bronchus sign (lesion) 64.4%
Diagnostic accuracy procedure 80.5% (157/195)





LUL, left upper lobe; RUL, right upper lobe; RML, right middle 
lobe; LLL, left lower lobe; RLL, right lower lobe.
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histology samples (range, 0–18) were acquired per procedure, 
equivaling an overall average of 11.39 samples (range, 1–25). 
In case they were used, collection of samples by forceps and 
1.1 mm cryobiopsy was performed an average of 7.08 and 
6.12 times per lesion, respectively. Brush and TBNA—both 
enabling ROSE—were used for repeat sampling a respective 
average of 1.64 and 3.26 times (Table 3). Overall outcome 
further showed that the forceps and TBNA sampling tools 
were used most of all tools, respectively having been used in 
89.3% and 73.3% of lesions (Figure 2 and Table 3). 
Rapid on-site evaluation of cytopathology
Rapid on-site evaluation of cytopathology was available in 
cases where sampling by brush and/or TBNA was performed 
(n=217). Of 79 lesions where cytology analysis was suggestive 
of malignancy, ROSE concluded similarly in 57 (69.8%). 
Due to the discrepancy between cytology results and overall 
pathology results, ROSE was able to conclude malignancy 
in 47.5% of cases where procedural outcome showed 
malignancy (57/120, Table 2). In the procedures where ROSE 
was found suggestive of malignancy, significantly more 
samples were obtained than where it did not (respective 
average of 12.65 vs. 10.51 samples, P=0.016, Table 3). The 
biopsy time insignificantly correlated to these findings, taking 
an average of 25.1 minutes in ROSE findings suggestive of 
malignancy and 24.2 minutes in non-confirmatory ROSE 
findings (P=0.36).
Discussion
In navigation bronchoscopies where access of lesions with 
a mean 15 mm size had been verified through (repeated) 
3D-imaging, we found that procedural pathology outcome 
corresponded to follow-outcome in 80.5% per patient (75.1% 
of lesions). An accurate diagnosis was most often obtained 
by forceps (accuracy 70.6%), followed by 1.1 mm cryoprobe 
(68.4%), TBNA (46.7%), 1.9 mm cryoprobe (41.2%), brush 
(30.3%) and lavage (23.7%). Our pair-wise comparison of 
tools showed a similar order of individual tool yield. By these 
findings, histology results alone were found representative 
of follow-up outcome in 72.4%, and by cytology in 49.3% 
of cases (Figure 2 and Table 3, P value <0.01). Due to the 
discordance of cytology findings with overall procedural 
findings, and ROSE again being discordant with cytology (in 
27.9% of cases), ROSE was able to help predict procedural 
malignant pathology outcome in only 47.5% of cases.
During the conduct of this study, (intermittent) 
3D-imaging verification was frequently used both after 
navigation and in-between repeated sampling. We 

































Cryo 1.1 mm 68.4% (26/38)
100%/100%  
(n=1, P=NA)
Cryo 1.9 mm 41.2% (21/51)
Figure 2 Sampling accuracy of different instruments as used in the navigation bronchoscopy procedure. Diagonal (grey boxes): accuracy 
of the individual instrument, as calculated over the amount of times the instrument was used (n/N). Top right half of table: Pair-wise 
comparison of tool accuracy, calculated by evaluation of cases where both tools were used in the same lesion. The individual tool accuracies 
as calculated by every time they were pair-wise used are shown in red (rows) and blue (columns). I.e. the first row shows how often lavage 
was accurate versus how often other tools were accurate (in red), when both were used (in blue). In between brackets (in black) the number 
of times the pair-wise tool comparison was available (as both tools were used in a single lesion), followed by probability of significant 
accuracy differences between the two tools. NA, not applicable; TBNA, trans-bronchial needle aspiration; Cryo, cryoprobe sampling; n, 
amount of cases; p, probability outcome of McNemar chi-squared test for pair-wise comparison of instruments.
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hypothesize the use of imaging in combination with 
maintained catheter position were essential in meticulous 
positioning and acquiring tissue at different sites of 
hypothesized pathology. It is likely only a minority of tissue 
samples contains pathologic tissue, as also indicated by 
Coghlin et al. in biopsy samples of visible lung cancers (13). 
The NAVIGATE study and a recent systematic review and 
meta-analysis substantiate these findings, finding a higher 
procedural success in cases of multi-modal and extensive 
sampling (12,31). We also found significantly more sampling 
was performed in lesions where an accurate diagnosis could 
be obtained (9.72 vs. 11.91 samples, P=0.014). Our repeated 
sampling with tools was based on clinical decision making 
rather than being a randomized and controlled trial. With 
the available tools having different properties, we deemed 
it relevant to tailor their use to the situation. In general, 
we chose our tools based upon relative positioning of the 
catheter to the lesion and secondary adjacent structures 
(e.g., pleura, vessels, cavities). When a central position 
in the lesion was obtained, a brush was generally the first 
choice (followed by secondary sampling tools). When lesion 
position was eccentric or trans-parenchymal access was 
deemed necessary, TBNA was often preferred first. The 
choice to not perform repeated TBNA, brush or lavage 
sampling more often was made consciously. EBUS-TBNA 
and ROSE literature has shown acquisition of more than 
4 TBNA samples in EBUS is of minimal additional value 
and sufficient for enabling molecular analysis in the vast 
majority of cases (32). While we cannot perform sampling 
under direct ultrasonic or video guidance, the motion and 
straightening of the catheter after needle insertion along 
with ROSE findings often being consistent in outcome 
from first to last biopsy made us decide on reducing routine 
TBNA use to 3–4 times. The choice of forceps and higher 
Table 2 Sampling outcome (per lesion) versus procedural and follow-up gold standard outcome
Pathology outcome—per lesion basis % n
Rapid on-site evaluation of cytopathology
ROSE correlating to malignant cytopathology findings 72.1% 57/79
ROSE correlating to procedural malignant findings (cytology & histology combined) 47.5% 57/120
Sampling accuracy in malignant lesions
Cytopathology (procedural) accuracy 48.5%* 79/163
Histopathology (procedural) accuracy 66.9%*,** 105/157
Combined pathology (procedural) accuracy 71.0% 120/169
Molecular analysis possible† 83.9% 26/31
Sampling accuracy in benign lesions
Cytopathology (procedural) accuracy 51.9%* 28/54
Histopathology (procedural) accuracy 88.6%*,** 47/53
Combined pathology (procedural) accuracy 87.5% 49/56
Sampling accuracy—lesions overall
Cytopathology (procedural) accuracy 49.3%* 107/217
Histopathology (procedural) accuracy 72.4%* 152/210
Overall pathology (procedural) accuracy 75.1% 169/225
Results of rapid on-site evaluation (ROSE) of cytopathology are described specifically for malignant disease findings as found per 
procedural cytopathology outcomes and overall procedural outcomes (being malignant). As clinical decision making decided on tool 
use, only cases where cytology or histology was available were used for calculation of accuracy. *, significant differences (P value <0.01, 
McNemar chi-squared test) between accuracies of cytology and histology in benign, malignant and lesions overall were found when 
assessing paired outcomes. **, significant difference (P value <0.01, unpaired two-sided Student’s t-test) between accuracy of histology 
outcomes in benign and malignant lesions. †, molecular analysis is only performed upon request (when clinically indicated), denoted here 
is the number of times it was possible when requested.
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amounts of repeat biopsy when compared to other tools 
was partially based on the observation that precurved 
catheters as used in this study lost least of their curvature 
by forceps, consequently allowing for biopsy of different 
sites. This could also provide for an explanation why we 
find a significant cytology and histology accuracy difference 
in both diagnosing benign and malignant lesions (Table 2). 
But where cytology accuracy was similar in malignant and 
benign lesions (48.5% vs. 51.9%, respectively), histology 
outcome was of higher variation (66.9% vs. 88.6% for 
malignant and benign outcomes, respectively). We cannot 
clearly explain this histology accuracy difference in benign 
and malignant findings, as it is also contrary to generalized 
findings of other studies (31). As such, additional research 
remains needed.
Procedural ROSE is likely of highest added value if 
feedback and communication between the interventional 
pulmonology and ROSE team is continuously had and a 
standardization of the process is agreed upon.  As previously 
found, the ROSE methodology may however differ among 
centers, with no evidence for preferring one above another 
smearing method (32). A meta-analysis by Mondoni et al. 
found ROSE increases the procedural yield also in diagnosis 
of peripheral lesions (15). Moreover, previous reports have 
shown that molecular analysis in EBUS-TBNA can be 
performed more often in a ROSE enhanced procedure (29). 
In this study, we uniquely use Cone beam CT imaging to 
verify in 3D that the lesion has been accurately accessed. 
Consecutively, extensive sampling was performed. Yet 
even after having (repeatedly) verified lesion access, a 
diagnosis indicative of procedural malignant outcome could 
be obtained by ROSE in only 47.5% of cases (Table 2). 
The discordant findings when related to procedural and 
cytology outcome may in part be explained by differences 
in available material. ROSE provides outcome on Giemsa 
staining, whilst additional material is harbored within 
Papanicolaou staining and cell block. Another cause of 
discordance might be related to the cytopathologist’s 
opinion that analysis of peripheral pulmonary lesion smears 
is different to that of EBUS-TBNA, being more diverse. 
Table 3 Descriptive statistics on procedural sampling techniques
Descriptive statistics on sampling techniques Mean (samples) Median (samples) Min–max (samples) Accuracy (tool)
Cytology 3.83 4 1–15 107/217 (49.3%)
Lavage 1.18 1 1–3 18/76 (23.7%)
Brush 1.64 2 1–4 40/132 (30.3%)
TBNA 3.26 3 1–11 77/165 (46.7%)
Histology 7.56 7 0–18 152/210 (72.4%)
Forceps 7.08 7 1–18 142/201 (70.6%)
Cryobiopsy (1.1 mm) 6.12 7 1–10 26/38 (68.4%)
Cryobiopsy (1.9 mm) 1.15 1 1–2 21/51 (41.2%)
Samples total 11.39 11 1–25 169/225 (75.1%)
ROSE: malignant findings 12.65† 12 4–24 –
ROSE: benign findings 10.51† 10 1–25 –
Unsuccessful diagnosis 9.72‡ 10 1–23 –
Successful diagnosis 11.91‡ 12 1–25 –
Tools total 2.93 3 1–6 –
Amount of sampling obtained are computed from cases where the instrument was used to acquire at least one sample. The accuracy 
are furthermore given by comparing the amount of times the instrument was used and led to an accurate diagnosis as compared against 
the total times it was used. On the bottom half of the table, the total amount of samples obtained for the different types of procedure 
characteristics are furthermore given; amount of samples when ROSE concluded malignancy, did not conclude malignancy, amount 
of samples in undiagnostic lesions and in cases where an accurate diagnosis could be obtained. †, P value =0.016, significantly more 
samples were obtained when ROSE had concluded malignancy; ‡, P value =0.014, significantly more samples were obtained in accurate 
procedures. TBNA, trans-bronchial needle aspiration; ROSE, rapid on-site evaluation of cytopathology.
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With decreasing lesion size and less solidity, differentiating 
between atypical findings and malignancy becomes more 
difficult (2). Combined, we can conclude that ROSE was 
of additional value in less than 50% of cases, and, that it 
was not associated with a reduction of total number of 
samples taken nor with biopsy time. However, having 
ROSE, the feedback obtained from our team enabled us 
to adapt our sampling strategy per nodule. The results 
of our study propose that more sampling is performed in 
cases where ROSE is confirmatory of malignancy. This is 
opposite to one would expect, as it should logically allow 
for earlier abandoning of additional sampling instead. With 
high chance of malignancy, we wanted to be sure to have 
sufficient tissue for a complete analysis in the modern era. 
Therein, even when we had a clear confirmation on the 
presence of malignancy and confirmation that the sample 
contained sufficient cells (or estimated DNA) for full 
analysis, we likely still obtained additional histology samples 
to maximize the chance of confirmatory outcome for the 
patient and avoid the possibility of needing re-biopsy. As 
a result, in these circumstances, having ROSE to confirm 
malignancy did not translate into less samples taken.
To our knowledge, this is one of first clinical trials to 
report on 1.1 mm cryoprobes for peripheral lesion biopsy 
in a through-the-catheter approach. Our initial experience 
with the 1.9 mm cryoprobe was cumbersome, as it often 
dislocated initial catheter position upon insertion due to 
probe rigidity. This especially was problematic in cases with 
tight instrument angulations, and could not be compensated 
for completely in several cases. Consequently, we feel the 
probe was often not as optimally positioned when compared 
to other instruments. What’s more, due to the probe’s size, 
the probe had to be removed together with the catheter 
for a single specimen removal. As a result, only one sample 
could be obtained at the end of the procedure. The newer 
1,1 mm cryoprobe allows for repeated sampling through the 
extended working channel, is much less rigid and as such; 
easier to use. As descriptively reported, a combination of 
TBNA with forceps biopsy in a curved guide sheath however 
deprecated the added value of also adding this tool to the 
inventory in 22 out of 24 cases where it was found diagnostic. 
It has previously been described that especially lesions non-
concentrically positioned around the bronchus would be 
benefitted by the cryoprobe (21). Our findings show this 
might be less valid for the smaller sized probe, which could 
be caused by its difference in area and tissue penetration.
Folch et al. and the NAVIGATE trial report a higher 
degree of sampling and multi-modal sampling led to higher 
yield (12,31). We report routinely sampling more than 
10 times per lesion in a multi-modal fashion and similarly 
see a higher amount of sampling correlating to finding an 
accurate diagnosis by procedural pathology more often (Table 
3, P=0.014). Our high degree of repeat sampling was in part 
based on our clinical findings that lesion access by imaging 
verification was frequent, but a confirmatory diagnosis 
could then not always be made. The hypothetic TBNA and 
forceps only scenario as presented in this study however 
shows we would have found 91.7% of eventual diagnoses by 
only using these two modalities. It could be suggested that 
not all lesions require extensive multi-modal sampling. Yet, 
it can also be concluded that no commercially and readily 
available tool is currently a do-it-all tool even if lesion access 
has been confirmed. Therefore, multi-modal and repeated 
sampling seems to remain the recommended methodology.
Conclusions
This study evaluates the outcome of different tissue sampling 
tools and ROSE in a subset of navigation bronchoscopies 
where 3D-imaging had verified lesion access in a routine 
clinical setting using widely available sampling tools. With 
repeated multimodal sampling, pathology outcome was 
found corresponding to gold standard follow-up outcome in 
75.1% of lesions, resulting in 80.5% of patients obtaining 
a representative diagnosis. In lesions where an accurate 
diagnosis could be obtained, significantly more sampling 
was performed (9.72 vs. 11.91 samples, P=0.014). An 
accurate diagnosis was most often obtained by forceps 
(accuracy 70.6%), followed by 1.1 mm cryoprobe (68.4%), 
TBNA (46.7%), 1.9 mm cryoprobe (41.2%), brush (30.3%) 
and lavage (23.7%). Analysis of a multi-modal sampling 
approach reveals sampling using only forceps and TBNA 
would have provided eventual diagnostic outcome in 91.7% 
of successfully diagnosed lesions. In cases where procedural 
pathology outcome proved malignant,  ROSE had 
precedingly confirmed malignancy in 47.5%. Confirmation 
of malignancy from ROSE during these procedures did not 
translate into a reduction of the number of biopsies taken or 
biopsy time. In conclusion, there is currently no single tool 
or methodology that is a do-it-all. Future research on how 
to improve the accuracy and effectivity of tissue sampling in 
navigation bronchoscopy is needed.
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